Biomarkers: Are They Useful in Severe Community-Acquired Pneumonia?
Semin Respir Crit Care Med
; 45(2): 200-206, 2024 Apr.
Article
em En
| MEDLINE
| ID: mdl-38196062
ABSTRACT
Community acquired pneumonia (CAP) is a prevalent infectious disease often requiring hospitalization, although its diagnosis remains challenging as there is no gold standard test. In severe CAP, clinical and radiologic criteria have poor sensitivity and specificity, and microbiologic documentation is usually delayed and obtained in less than half of sCAP patients. Biomarkers could be an alternative for diagnosis, treatment monitoring and establish resolution. Beyond the existing evidence about biomarkers as an adjunct diagnostic tool, most evidence comes from studies including CAP patients in primary care or emergency departments, and not only sCAP patients. Ideally, biomarkers used in combination with signs, symptoms, and radiological findings can improve clinical judgment to confirm or rule out CAP diagnosis, and may be valuable adjunctive tools for risk stratification, differentiate viral pneumonia and monitoring the course of CAP. While no single biomarker has emerged as an ideal one, CRP and PCT have gathered the most evidence. Overall, biomarkers offer valuable information and can enhance clinical decision-making in the management of CAP, but further research and validation are needed to establish their optimal use and clinical utility.
Texto completo:
1
Coleções:
01-internacional
Contexto em Saúde:
11_ODS3_cobertura_universal
/
4_TD
Base de dados:
MEDLINE
Assunto principal:
Pneumonia
/
Pneumonia Viral
/
Infecções Comunitárias Adquiridas
Tipo de estudo:
Prognostic_studies
Limite:
Humans
Idioma:
En
Revista:
Semin Respir Crit Care Med
Ano de publicação:
2024
Tipo de documento:
Article